EXACT Sciences Building A Better Screening Test - Initiating With A Buy And $10 Target

According to Auriga, EXACT Sciences Corp. EXAS is building a better screening test and initiating with a Buy and $10 target. Auriga reported that EXAS is developing Cologuard, a stool-based test for Colorectal Cancer (CRC) screening, a potential $1 billion-plus market opportunity. “Clinical data to date has been impressive, demonstrating 85% sensitivity for cancer and 64% sensitivity for pre-cancer –putting Cologuard among the highest sensitivity and specificity screening tests on the market. EXAS continues to improve performance attributes, and we expect the locked assay to demonstrate 85% to 90% sensitivity for cancer and 64% sensitivity for pre-cancer in a large, prospective 10,000 patient clinical trial (3Q11 start). Putting these detection rates into a convenient, noninvasive platform, should fit well within the CRC screening market and enable EXAS to ultimately capture 30% of the estimated 12 million annual stool screens.” EXACT Sciences closed yesterday at $5.43.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsAurigaBiotechnologyConsumer DiscretionaryEXACT SciencesHealth CareHome Furnishings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!